MARKET

UROV

UROV

UROVANT SCIENCES LTD.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.63
+0.10
+1.05%
Opening 14:19 09/18 EDT
OPEN
9.42
PREV CLOSE
9.53
HIGH
9.93
LOW
9.20
VOLUME
17.04K
TURNOVER
--
52 WEEK HIGH
14.49
52 WEEK LOW
4.055
MARKET CAP
289.14M
P/E (TTM)
-2.6870
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of UROV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

UROV News

  • 71 Biggest Movers From Yesterday
  • Benzinga.6d ago
  • Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
  • Business Wire.09/06 14:00
  • Urovant Sciences Limited (UROV) CEO Keith Katkin on Q1 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.08/14 01:48
  • Urovant Sciences Ltd (UROV) Q1 2019 Earnings Call Transcript
  • Motley Fool.08/14 01:23

More

Industry

Biotechnology & Medical Research
-1.63%
Pharmaceuticals & Medical Research
-0.58%

Hot Stocks

Name
Price
%Change

About UROV

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Company’s subsidiaries include Urovant Sciences, Inc., Urovant Holdings Limited, and Urovant Sciences GmbH.
More

Webull offers Urovant Sciences Ltd (UROV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.